Allakos Subcutaneous Therapy for Mast Cells-Related Diseases 'Well-Tolerated;' Shares Up After Hours

MT Newswires Live10-11

Allakos (ALLK) said Thursday results of a phase 1 trial showed that a subcutaneously administered AK006, its investigational monoclonal antibody that selectively inhibits mast cells, was "well-tolerated with a favorable safety profile."

The company reported data from single dose subcutaneous AK006 up to 720 milligrams, with skin biopsies taken from treated healthy volunteers showing high levels of receptor occupancy, confirming that AK006 reached skin tissue mast cells. The results were consistent with the trial of intravenously-administered AK006, it said.

The results showed there were no serious adverse events in subjects, no treatment emergent adverse events leading to discontinuation of AK006, and no dose limiting toxicities, Allakos said.

The company expects topline phase 1 results of intravenous AK006 in patients with chronic spontaneous urticaria in early Q1 next year.

Shares of the company were advancing over 7% in extended trading.

Price: 0.7076, Change: +0.05, Percent Change: +7.37

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474731772?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-11 04:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474731772","market":"sh","top_or_hot":-1,"title":"Allakos Subcutaneous Therapy for Mast Cells-Related Diseases 'Well-Tolerated;' Shares Up After Hours","media":"MT Newswires Live","content":"<html><body><p> Allakos (ALLK) said Thursday results of a phase 1 trial showed that a subcutaneously administered AK006, its investigational monoclonal antibody that selectively inhibits mast cells, was \"well-tolerated with a favorable safety profile.\"</p><p>The company reported data from single dose subcutaneous AK006 up to 720 milligrams, with skin biopsies taken from treated healthy volunteers showing high levels of receptor occupancy, confirming that AK006 reached skin tissue mast cells. The results were consistent with the trial of intravenously-administered AK006, it said.</p><p>The results showed there were no serious adverse events in subjects, no treatment emergent adverse events leading to discontinuation of AK006, and no dose limiting toxicities, Allakos said.</p><p>The company expects topline phase 1 results of intravenous AK006 in patients with chronic spontaneous urticaria in early Q1 next year.</p><p>Shares of the company were advancing over 7% in extended trading.</p><p>Price: 0.7076, Change: +0.05, Percent Change: +7.37</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allakos Subcutaneous Therapy for Mast Cells-Related Diseases 'Well-Tolerated;' Shares Up After Hours</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllakos Subcutaneous Therapy for Mast Cells-Related Diseases 'Well-Tolerated;' Shares Up After Hours\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-11 04:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Allakos (ALLK) said Thursday results of a phase 1 trial showed that a subcutaneously administered AK006, its investigational monoclonal antibody that selectively inhibits mast cells, was \"well-...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2474731772","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474731772","pubTimestamp":1728593739,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Allakos  said Thursday results of a phase 1 trial showed that a subcutaneously administered AK006, its investigational monoclonal antibody that selectively inhibits mast cells, was \"well-tolerated with a favorable safety profile.\"The company reported data from single dose subcutaneous AK006 up to 720 milligrams, with skin biopsies taken from treated healthy volunteers showing high levels of receptor occupancy, confirming that AK006 reached skin tissue mast cells. The results were consistent with the trial of intravenously-administered AK006, it said.The results showed there were no serious adverse events in subjects, no treatment emergent adverse events leading to discontinuation of AK006, and no dose limiting toxicities, Allakos said.The company expects topline phase 1 results of intravenous AK006 in patients with chronic spontaneous urticaria in early Q1 next year.Shares of the company were advancing over 7% in extended trading.Price: 0.7076, Change: +0.05, Percent Change: +7.37","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ALLK":"Allakos Inc."},"translate_title":"Allakos皮下治疗肥大细胞相关疾病耐受性良好；“盘后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLK":0.9},"content_text":"Allakos (ALLK) said Thursday results of a phase 1 trial showed that a subcutaneously administered AK006, its investigational monoclonal antibody that selectively inhibits mast cells, was \"well-tolerated with a favorable safety profile.\"The company reported data from single dose subcutaneous AK006 up to 720 milligrams, with skin biopsies taken from treated healthy volunteers showing high levels of receptor occupancy, confirming that AK006 reached skin tissue mast cells. The results were consistent with the trial of intravenously-administered AK006, it said.The results showed there were no serious adverse events in subjects, no treatment emergent adverse events leading to discontinuation of AK006, and no dose limiting toxicities, Allakos said.The company expects topline phase 1 results of intravenous AK006 in patients with chronic spontaneous urticaria in early Q1 next year.Shares of the company were advancing over 7% in extended trading.Price: 0.7076, Change: +0.05, Percent Change: +7.37","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474731772"}